{Reference Type}: Journal Article
{Title}: Evaluation of the safety and efficacy of direct oral anticoagulants compared with vitamin-k antagonists in the treatment of left ventricular thrombosis. A systematic review and meta-analysis.
{Author}: Mehrpooya M;Barakzehi MR;Nikoobakhsh M;
{Journal}: Heart Lung
{Volume}: 67
{Issue}: 0
{Year}: 2024 Sep-Oct 15
{Factor}: 3.149
{DOI}: 10.1016/j.hrtlng.2024.04.019
{Abstract}: <B>BACKGROUND: </B>Since the introduction of direct oral anticoagulants (DOACs) and their comparison with vitamin K antagonists (VKAs), conflicting results have been reported regarding the optimal treatment for left ventricular thrombosis (LVT).<BR><B>OBJECTIVE: </B>In this meta-analysis, we intend to comprehensively evaluate the safety and efficacy of these treatments.<BR><B>METHODS: </B>All clinical trials and cohorts that compared the efficacy or safety of VKAs with DOACs in the treatment of LVTs were systematically searched until April 15, 2023.<BR><B>RESULTS: </B>The results of 32 studies with a pooled sample size of 4213 patients were extracted for meta-analysis. DOACs, especially rivaroxaban and apixaban, cause faster resolution, lower mortality, and fewer complications (SSE and bleeding events) than VKAs in the management of LVTs.<BR><B>CONCLUSIONS: </B>Compared with VKAs, DOACs result in significantly faster (only rivaroxaban) and safer resolution of left ventricular thrombosis.